BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $36.5714.

A number of research firms recently weighed in on BIOA. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Needham & Company LLC lowered their target price on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Finally, BTIG Research restated a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research report on Monday, August 3rd.

BioAge Labs Stock Down 6.8%

Shares of NASDAQ BIOA opened at $10.67 on Wednesday. The stock has a market capitalization of $489.75 million, a price-to-earnings ratio of -4.48 and a beta of 0.93. BioAge Labs has a 52 week low of $4.33 and a 52 week high of $25.95. The firm has a 50-day moving average price of $19.81 and a 200 day moving average price of $19.04.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The company had revenue of $2.45 million for the quarter. Equities research analysts expect that BioAge Labs will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its position in BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of BioAge Labs during the second quarter valued at $64,000. Marshall Wace LLP raised its stake in BioAge Labs by 324.7% in the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock valued at $937,000 after purchasing an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares in the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of BioAge Labs during the 2nd quarter worth about $182,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.